429 related articles for article (PubMed ID: 24996452)
1. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
[TBL] [Abstract][Full Text] [Related]
2. Analysis of vaccine stability.
Volkin DB; Burke CJ; Sanyal G; Middaugh CR
Dev Biol Stand; 1996; 87():135-42. PubMed ID: 8854010
[TBL] [Abstract][Full Text] [Related]
3. Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms.
Hickey JM; Sahni N; Toth RT; Kumru OS; Joshi SB; Middaugh CR; Volkin DB
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():23-38. PubMed ID: 27071526
[TBL] [Abstract][Full Text] [Related]
4. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants.
Braun LJ; Tyagi A; Perkins S; Carpenter J; Sylvester D; Guy M; Kristensen D; Chen D
Vaccine; 2009 Jan; 27(1):72-9. PubMed ID: 18973782
[TBL] [Abstract][Full Text] [Related]
5. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
Fox CB
Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
[TBL] [Abstract][Full Text] [Related]
6. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
[TBL] [Abstract][Full Text] [Related]
7. Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay.
Schlehuber LD; McFadyen IJ; Shu Y; Carignan J; Duprex WP; Forsyth WR; Ho JH; Kitsos CM; Lee GY; Levinson DA; Lucier SC; Moore CB; Nguyen NT; Ramos J; Weinstock BA; Zhang J; Monagle JA; Gardner CR; Alvarez JC
Vaccine; 2011 Jul; 29(31):5031-9. PubMed ID: 21616113
[TBL] [Abstract][Full Text] [Related]
8. Formulation, stability, and delivery of live attenuated vaccines for human use.
Burke CJ; Hsu TA; Volkin DB
Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898
[TBL] [Abstract][Full Text] [Related]
9. Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
Dalençon F
Hum Vaccin Immunother; 2013 Sep; 9(9):2013-4. PubMed ID: 23938771
[TBL] [Abstract][Full Text] [Related]
10. Liposomal adjuvants: preparation and formulation with antigens.
Haensler J
Methods Mol Biol; 2010; 626():73-90. PubMed ID: 20099122
[TBL] [Abstract][Full Text] [Related]
11. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
12. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
[TBL] [Abstract][Full Text] [Related]
13. A heat-stable hepatitis B vaccine formulation.
Jezek J; Chen D; Watson L; Crawford J; Perkins S; Tyagi A; Jones-Braun L
Hum Vaccin; 2009 Aug; 5(8):529-35. PubMed ID: 19556877
[TBL] [Abstract][Full Text] [Related]
14. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
Collin N; Dubois PM
Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.
Nelson CM; Wibisono H; Purwanto H; Mansyur I; Moniaga V; Widjaya A
Bull World Health Organ; 2004 Feb; 82(2):99-105. PubMed ID: 15042231
[TBL] [Abstract][Full Text] [Related]
16. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations.
Vecchi S; Bufali S; Skibinski DA; O'Hagan DT; Singh M
J Pharm Sci; 2012 Jan; 101(1):17-20. PubMed ID: 21918987
[TBL] [Abstract][Full Text] [Related]
17. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges.
Tlaxca JL; Ellis S; Remmele RL
Adv Drug Deliv Rev; 2015 Oct; 93():56-78. PubMed ID: 25312673
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates.
Scherließ R; Ajmera A; Dennis M; Carroll MW; Altrichter J; Silman NJ; Scholz M; Kemter K; Marriott AC
Vaccine; 2014 Apr; 32(19):2231-40. PubMed ID: 24631078
[TBL] [Abstract][Full Text] [Related]
19. Exposure to heat and freezing in the vaccine cold chain in Thailand.
Techathawat S; Varinsathien P; Rasdjarmrearnsook A; Tharmaphornpilas P
Vaccine; 2007 Jan; 25(7):1328-33. PubMed ID: 17157419
[TBL] [Abstract][Full Text] [Related]
20. Stability of collapse lyophilized influenza vaccine formulations.
Anamur C; Winter G; Engert J
Int J Pharm; 2015 Apr; 483(1-2):131-41. PubMed ID: 25660049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
